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a b s t r a c t
This comprehensive review compiles published data from 62 original articles comparing different HPV
tests and one meta-analysis on the clinical performance of the Aptima HR HPV (AHPV) assay in either
screening or referral populations as well as for the purpose of test of cure. A number of publications
with technical issues were also considered. Besides a brief introduction in the development of E6/E7
mRNA testing, the review summarizes data on analytical sensitivies and speciﬁcities, as well as on clin-
ical sensitivity, speciﬁcity, NPV and PPV with histological endpoints CIN2+ and CIN3+, where available.
Although most studies were of cross-sectional design, ﬁve studies with a longitudinal prospective design
or component were identiﬁed. In addition to the study design, sample size, age and CIN2/3+ prevalence
of the respective cohort are listed. This allows direct comparison of the published data in the respective6/E7 mRNA groups. One major outcome of this review is the remarkably stable similar sensitivities of AHPV and
HC2 independent from study design for detection of CIN2/3+ combined with a higher speciﬁcity of the
AHPV. The second outcome was the longitudinal predictive value derived from registry linkage and other
prospective studies that would support the applicability of the AHPV test in primary screening with at
least a three year screening interval.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
E6 and E7 oncogene expression of human papillomavirus (HPV)
et al. later demonstrated the ubiquitous presence of E6 and E7 tran-
scripts of a number of high-risk (HR) HPV types in the vast majority
of testedneoplastic cervical specimens [2]. Subsequently, a numberype 16 as a marker for neoplasia has ﬁrst been described in 1986,
hen E6/E7 transcripts were detected in a cervical cancer-derived
ell line and a biopsy of cervical carcinoma tissue [1]. Nakagawa
∗ Corresponding author at: Division of Experimental Virology, Medical Virology,
niversity Hospital Tübingen, Elfriede-Aulhorn-Str. 6, 72076 Tübingen, Germany.
ax: +49 7071 295419.
E-mail address: thomas.iftner@med.uni-tuebingen.de (T. Iftner).
ttp://dx.doi.org/10.1016/j.jcv.2015.10.027
386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article
/).of studies conﬁrmed that E6/E7 expression represents a key feature
of neoplastic progression and correlated a highermRNA expression
with increasingdisease severity (summarizedby [3]). In2004Sotlar
et al. published a nested reverse transcription (RT) multiplex PCR
protocol for the combined detection of E6/E7 mRNA of the 18HPV
types 6/11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66
and 68 [4] and demonstrated its potential as a sensitive diagnos-
tic tool for cervical intraepithelial neoplasia (CIN) [5]. The authors
also showed that E6/E7 mRNA measurement is more sensitive in
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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etecting disease than HPV DNA detection by conventional PCR
ith MY09/MY11 and GP5+/GP6+ primers. DNA-based HPV tests
an only discriminate between presence and absence of a HPV-
peciﬁc DNA target-sequence and cannot determine whether an
nfection is active or even potentially transforming. As E6/E7mRNA
xpressiononly occurs in actively infected cells andgross transcript
evels increase during CIN development and progression, it was
ypothesized that HPV mRNA measurement might be more spe-
iﬁc in detecting high-grade disease. Indeed the ﬁrst commercially
vailable test that utilizes E6/E7 mRNA detection demonstrated
igniﬁcantly higher clinical speciﬁcities than the HPV DNA-based
omparative HR HPV type group tests [6–10]. The PreTectTM HPV-
roofer assay (NorChip AS, Klokkarstua, Norway), which was also
arketed under the name NucliSENS EasyQ® HPV by bioMérieux
France) is a real-time multiplex assay that uses nucleic acid
equence based ampliﬁcation (NASBA)—a sensitive transcription-
ased ampliﬁcation system (TAS) for the speciﬁc in vitro replication
f mRNA. The assay employs this technology in conjunction with
olecular beacon probes allowing the direct qualitative detection
f HPV oncogene expression of the ﬁveHR-HPV types 16, 18, 31, 33,
nd 45 with simultaneous genotype-speciﬁc identiﬁcation. These
ve target HPV types have been found in only 75.1% of CIN2/3 and
8.5% of squamous cell carcinomas (SCC) [11,12], which is, how-
ver, also the reason for the test’s inferior sensitivity for detecting
ervical disease and the higher speciﬁcity in comparisonwith other
PV tests [9,10,13].
In 2008 another commercially available mRNA detection assay
as launched. The APTIMA® HPV Assay (AHPV; Hologic, San Diego,
A) is a target ampliﬁcation assay utilizing transcription-mediated
mpliﬁcation (TMA) for the qualitative detection of the viral poly-
istronic E6/E7 mRNA from 14HPV types. In addition, the APTIMA®
PV 16 18/45 Genotype Assay (AHPV-GT; Hologic, San Diego, CA)
mploys the TMA technology for type-speciﬁc detection of HPV
ypes 16 and 18/45.
This review provides an overview of the published literature
bout both, the AHPV assay and the AHPV-GT test.
. AHPV methodology
The Aptima HPV assay involves three consecutive steps, which
ake place in a single tube: target capture specimen process-
ng; target ampliﬁcation by transcription-mediated ampliﬁcation
TMA) [14] and detection of the ampliﬁcation products by the
ybridization protection assay (HPA) [15]. The assay incorporates
n internal control for nucleic acid capture, ampliﬁcation, and
etection, as well as operator or instrument error. After cell lysis
he target mRNA is isolated from the specimen by sequence-
peciﬁc capture oligomers that also contain a deoxyadenosine tail.
uring the hybridization step, capture oligomers bind to speciﬁc
ucleotide sequences of target E6/E7 mRNA molecules. Oligomer-
arget complexes are then captured by decreasing the temperature
f the reaction to room temperature, which allows hybridiza-
ion of the deoxyadenosine region of the capture oligomer to
oly-deoxythymidine molecules covalently attached to magnetic
articles. After target capture, the HPV mRNA is ampliﬁed via TMA,
hich involves the two enzymes MMLV reverse transcriptase and
7 RNA polymerase. The reverse transcriptase generates a DNA
opy of the targetmRNA sequence containing a promoter sequence
or T7RNApolymerase. T7RNApolymerase thenproducesmultiple
opies of RNA amplicons from the DNA copy template. Detection
f the RNA amplicons is achieved by the hybridization protection
ssay (HPA) using single-stranded nucleic acid probes comple-
entary to the amplicon. After inactivating unhybridized probes,
NA:DNA hybrids are detected as photon signals by luminomet-
ic measurements. Internal control signals are discriminated fromal Virology 76 (2016) S40–S48 S41
the HPV signals by employing probes with different light emis-
sion kinetics (ﬂasher vs glower). The dual kinetic assay (DKA) then
differentiates between the signals from both labels. Results are
reported as relative light units (RLU).
The AHPV assay may be run on the semi-automated direct
tube sampling (DTS®) system (Hologic) as well as on the TIGRIS®
DTSTM (Hologic) or the PANTHER® platform (Hologic), which fully
automate the target capture specimen processing, TMA and DKA
detection steps.
3. Aptima HPV Assay vs Aptima HPV 16 18/45 Genotype
Assay
In 2011 the US Food and Drug Administration (FDA) approved
the AHPV assay for usage in women 30 years and older, and for
women between 21 and 29 years of age with ASC-US, in order to
determine the requirement of additional follow-up and diagnostic
or treatment procedures (http://www.fda.gov/medicaldevices/
productsandmedicalprocedures/deviceapprovalsandclearances/
recently-approveddevices/ucm278520.htm). The AHPV group
test has been tailored for combined detection of HPV types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. These
fourteen types have been classiﬁed as group 1 (carcinogenic),
group 2A (probably carcinogenic) or group 2B (possibly carcino-
genic) carcinogenic for humans by the IARC [16]. In contrast, the
AHPV-GT assay has been designed for type-speciﬁc detection
of HPV type 16 and for combined detection of HPV types 18
and 45. These types have been shown to be prevalent in 94% of
cervical adenocarcinoma cases [17]. The AHPV-GT assay received
approval from the FDA in 2012 for application in women with
AHPV-positive test results. (http://www.fda.gov/medicaldevices/
productsandmedicalprocedures/deviceapprovalsandclearances/
recently-approveddevices/ucm325771.htm). Both tests have also
been labelled for marketability within the European Economic
Area. The CE mark indicates conformity of a given test with Euro-
pean law, constitutes no approval and is therefore different from
the FDA approval process. The FDA guidelines for market approval
of in vitro diagnostic devices for the detection of HPV require
that the respective test is both safe and effective by evaluating
analytical and clinical performance data (http://www.fda.gov/
RegulatoryInformation/Guidances/ucm181509.htm).
4. Analytical performance
Analytical performance of the AHPV assay has been thor-
oughly evaluated for samples collected in Cytyc ThinPrep® Pap test
PreservCyt® Solution (Hologic Inc., Bedford, MA; hereafter: Pre-
servCyt) [18,19]. As a result the analytical sensitivity of the AHPV
assay was less than 200 copies of HPV transcripts per reaction
for most target types [18]. Analytical sensitivity for the detection
of E6/E7 mRNA was much higher than for E6/E7 DNA, and DNA
detection was 1000–3000 times lower as compared to the HC2
test [19]. Indeed the analytical sensitivity for the detection of HPV
16, 18 and 45 was higher for the AHPV assays than for the Hybrid
Capture 2 (HC2) test (Hilden, Germany) [20]. The analytical speci-
ﬁcity was 99% with virtually no cross-reactivity with low-risk (LR)
HPV types or other pathogens and selected species of the nor-
mal microbiological Human ﬂora, but cross-reactivity with less
deﬁned typesHPV26, 53 and82 regarding carcinogenicity has been
described [21]. Furthermore, interference with assay performance
was excluded for substances frequently applied to the genital area
[18,22] and has only been observed for polyquaterium 15, a com-
pound found in few personal lubricants [18]. A sufﬁcient analytical
performance was also recently conﬁrmed for the AHPV-GT assay
[23].
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. Suitability of different collection media
The majority of clinical and analytical data are based on
amples collected in PreservCyt medium and only few studies
re available for other transport media. Additional performance
ata are for example available for samples collected in Digene
pecimen transport medium (D-STM), which was found to be
cceptable for AHPV testing with the restriction to non-denatured
amples [19]. Direct comparison data of the suitability of different
ransport media are only available from one study. Chernesky et al.
ompared AHPV test performances using three samples from each
f 580 women, collected in either PreservCyt, TriPath Imaging®
urePath® Preservative Fluid (BectonDickinson Co., Franklin Lakes,
J; hereafter: SurePath) and the Aptima specimen collection and
ransport kit (SCT) [24]. Agreement between the test results using
ifferent collection media was excellent. However, the results
btained from SurePath specimens yielded fewer positive events
ompared to the two comparative media, which is evidenced by
signiﬁcantly lower kappa-value for SurePath vs SCT ( =0.72,
5% conﬁdence interval (CI): 0.66–0.78) in comparison to Pre-
ervCyt vs SCT ( =0.82, 95%CI: 0.77–0.86) and a lower sensitivity
or CIN2+ in SurePath versus PreservCyt (Table 1). The slightly
nferior performance of AHPV using SurePath samples was also
emonstrated in a large study comparing various HPV detection
ssays in two sets of specimens collected in either PreservCyt or
urePath medium [25]. The authors reported a marginally reduced
linical sensitivity relative to the performance of the HC2 test
n SurePath than in PreservCyt samples. A similar effect on the
linical sensitivity of the AHPV assay was seen in the HORIZON
tudy, where SurePath samples were collected and tested by four
ifferent HPV tests [26,27]. In the latter study, the AHPV assay
as found to have a signiﬁcantly lower clinical sensitivity in
etecting CIN2+ and CIN3+ in comparison to the HC2 test (Fig. 1).
he most probable reason for this inferior performance using
urePath samples is the fact, that it contains a ﬁxative agent, which
ross-links cellular proteins and nucleic acids, leading to an aggra-
ation of the target capture reaction due to less easily accessible
RNA [28]. Moreover, the manufacturer-recommended treatment
f SurePath samples with Proteinase K prior to performing the
HPV assay in order to reverse the cross-linking process appears
nsufﬁcient, considering recently published data [24,26,27]. A
ore efﬁcient pre-treatment protocol was recently CE marked
29]. More importantly, the use of SurePath medium has also
een reported to interfere with DNA-based HPV test performances
ncluding the HC2 test, which is why the FDA has so far approved
he application of SurePath medium only for cytology [30,
ttp://www.fda.gov/downloads/aboutfda/reportsmanualsforms/
eports/ucm472777.pdf+surepath&client=FDAgov
proxystylesheet=FDAgov&output=xml no dtd&site=
DAgov&ie=UTF-8&access=p&oe=UTF-8]
. Clinical performance
An ideal HR-HPV test for identiﬁcation of HPV-associated dis-
ase that needs treatment has to combine high clinical sensitivity
ith high clinical speciﬁcity. Clinical sensitivity is different from
he analytical sensitivity of a given test system, as a test with a
ood clinical sensitivity usually has a higher cut-off for being pos-
tive than the analytical detection threshold that separates signal
rom noise. Therefore, clinical trials are needed to deﬁne the cut-
ff for the clinical sensitivity, which separates latent and clinically
rrelevant infections from transforming infections with underlying
igh grade disease. However, as HPV infections are quite common
nd not all HPV infections cause disease and have a high tendency
or spontaneous regression, the positive predictive value, which isal Virology 76 (2016) S40–S48
the likelihood that a test-positive person has disease, is for all HPV
tests rather low. As cervical cancer is the rare outcomeof a common
infection with HR HPV types, in a well screened routine screening
population the negative predictive value, which is the percentage
of all people, who test negative and have no disease, is high for all
screening tests including cytology. The prevalence of disease in the
screened population, however, has a major impact on the clinical
speciﬁcity. In a routine screening population of women aged 30
years and older with usually up to 1% of CIN2+ lesions, the speci-
ﬁcity of the AHPV test is well above 85%. In referral populations,
the much higher prevalence of disease causes a dramatic decrease
in clinical speciﬁcity which might reach levels of 20%. This happens
due to the increased prevalence, which diminishes the denomina-
tor in thecalculation for the speciﬁcity (allwomenwithoutdisease).
Therefore, it is important not to compare PPV and clinical speci-
ﬁcity (which are directly linked to each other) from studies using
screening populations with those from populations where individ-
uals were referred because of abnormal cytology, or had a test of
cure. The FDA guidelines for market approval have been backed by
the “Guidelines for human papillomavirus DNA test requirements
for primary cervical cancer screening inwomen30 years and older”
published by Meijer et al., which sets standards for the respective
new HPV DNA test’s clinical performance in relation to the gold-
standard HC2 or GP5+/6+ test [31]. According to these criteria, a
validation study has been performed in comparison to GP5+6+
PCR conﬁrming AHPV’s high intra-laboratory reproducibility over
time (96.0%) and a 96.7% inter-laboratory agreement of the AHPV
assay [32]. Earlier, the AHPV assay performed robustly in an inter-
instrument, -operator, -lot and -run reproducibility study [18].
Heideman et al. also conﬁrmed the non-inferior clinical perfor-
mance [32]. In addition, clinical sensitivity, speciﬁcity and negative
and positive predictive values of the AHPV test have been thor-
oughly evaluated in comparison to liquid based cytology (LBC) and
otherHPVnucleic acid tests and respective studies are summarized
in Table 1. HPV testing in general is an established tool for the triage
of borderline cytology results and national cervical cancer screen-
ing guidelines have been adapted accordingly in many countries
[33,34]. Hence, the majority of comparison studies have been per-
formed in referral populations (Table 1). On the other hand, HPV
testing becomes increasingly valuable for primary cervical cancer
screening, as shown by the large number of randomized controlled
trials (RCTs)providingevidence thatHPV testing reducesCIN3+and
cervical cancer in the second screening round [35–39] and with the
large US-based Athena trial [40,41] leading to the FDA-approval
of the cobas 4800HPV test (Roche Molecular Systems, Pleasan-
ton, CA) with concurrent HPV16/18 genotyping for application in
primary screening (http://www.fda.gov/newsevents/newsroom/
pressannouncements/ucm394773.htm, [9]).
A number of comparison studies using the AHPV test have been
conducted in routine screening populations (Table 1). Another pop-
ulation, which beneﬁts from HPV testing are women that have
completed treatment for prevalent CIN or cancer and few studies
have been reported for AHPV in test-of-cure populations (Table 1).
Despite these diverse populations and varying study designs, the
AHPV test consistently shows similar sensitivities for CIN2+ or
CIN3+. In comparison with other HPV tests, the AHPV test repeat-
edly has equivalent clinical sensitivity, but superior speciﬁcity for
the detection of cervical disease (CIN2+/CIN3+) (Table 1). This is
especially evident when the comparison is restricted to the gold-
standardHC2 test,where themajority of available studies report an
insigniﬁcantly lower to equal sensitivity and a signiﬁcantly higher
speciﬁcity for the AHPV test (Fig. 1). These results are supported by
meta-analysis data [8] and previous review reports [9,42–45]. The
only deviations are reported from studies using SurePath samples
(Moss et al. [25], Rebolj et al. [27] and Rebolj et al. [26]) as described
above (Table 1 and Fig. 1).
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Table 1
Summary of studies reporting clinical performance data on the AHPV assay stratiﬁed by study population.
Citation Population Endpoint Test Sensitivity Speciﬁcity NPV PPV Collection medium
Type Na Age Type N (rate) Type Split sample
Screening population
Wu et al. [61]
(SHENCCAST I)
Screening 2000 25–59 CIN2+ 27 (0.014) HC2 88.9 84.5 PreservCyt Partially
AHPV 100 91.2 PreservCyt
LBC 66.7 95.5 SurePath
Ratnam et al. [62] Screening 1373 16–81 CIN2+ 7 (0.005) HC2 100 85.2 PreservCyt Yes
AHPV 100 88.4
Monsonego et al.
[63] (FASE)
Screening 4429 20–65 CIN2+ 101 (0.023) HC2 96.7b 86.4b PreservCyt Yes
AHPV 92.0b 91.8b
LBC 69.1b 91.9b
CIN3+ 27 (0.006) HC2 95.3b 84.9b
AHPV 95.7b 90.3b
LBC 73.3b 90.8b
Monsonego et al. [64] (FASE) 5006 Absolute and relative risk analysis between HC2, AHPV and LBC
Nieves et al. [65]
(MECCS II)
Screening 2049 30–50 CIN3+ 16 (0.008) HC2 100 92.2 9.2 PreservCyt Yes
AHPV 100 93.5 10.7
LBC 87.5 94.1 10.5
Cuzick et al. [46] Screening 6000 20–66 CIN2+ 40 (0.007) HC2 97.5 85.4 4.3 PreservCyt Yes
rtHPV 95.0 87.2 4.7
BD HPV 97.5 84.3 4.0
Cobas 97.5 84.5 4.1
AHPV 97.5 90.2 6.3
CIN3+ 19 (0.003) HC2 100 2.1
rtHPV 94.7 2.2
BD HPV 100 2.0
Cobas 100 2.0
AHPV 100 3.1
Rebolj et al. [28] (Horizon) Screening 5070 16–89 Agreement analysis between HC2 and AHPV
Rebolj et al. [66] (Horizon) Screening 5064 Unknown Agreement analysis between HC2, cobas, CLART and AHPV SurePath Yes
Rebolj et al. [26]
(Horizon)
Screening 1278 23–29 CIN2+ 68 (0.053) HC2 94.0 72.0
AHPV 85.0 77.0
Cobas 99.0 62.0
CLART 99.0 66.0
CIN3+ 44 (0.034) HC2 95.0 71.0
AHPV 82.0 75.0
Cobas 98.0 61.0
CLART 100 65.0
Munson et al. [67] Screening 4056 ≥20 Agreement analysis between Cervista and AHPV PreservCyt Yes
Pyne et al. [23] Screening 967 >30 Analytical performance comparison between HC2 and AHPV PreservCyt Yes
Iftner et al. [52]
(GAST)
Screening 9451 30–60 CIN2+ 90 (0.010) HC2 93.2b 94.9b 99.9b 17.9b PreservCyt Yes
AHPV 87.8b 96.1b 99.8b 21.1b
LBC 39.5b 98.4b 99.3b 22.7b
CIN3+ 43 (0.005) HC2 100b
AHPV 90.9b
LBC 49.8b
Reid et al. [58]
(CLEAR)
Screening, 3-year
f-up
10,509 30–89 CIN2+ 47 (0.004) HC2 63.6 94.8 PreservCyt Yes
AHPV 55.3 96.3
CIN3+ 23 (0.002) HC2 81.8 94.7
AHPV 78.3 96.2
Referral population
Szarewski et al.
[68] (Predictors 1)
Referral 953 18–67 CIN2+ (∼0.280) HC2 99.6 28.4 36.1 PreservCyt Yes
Amplicor 98.9 21.7 33.5
AHPV 95.2 42.2 39.9
LA 98.2 32.8 37.7
S44
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Table 1 (Continued)
Citation Population Endpoint Test Sensitivity Speciﬁcity NPV PPV Collection medium
Type Na Age Type N (rate) Type Split sample
CLART 80.9 37.1 33.0
LBC 93.8 58.1 47.3
CIN3+ (∼0.200) HC2 99.5 25.4 25.6
Amplicor 99.5 19.7 23.5
AHPV 97.4 38.8 28.9
LA 99.0 29.6 26.9
CLART 83.9 36.0 24.0
LBC 95.9 53.2 34.2
Szarewski et al.
[47] (Predictors 2)
1099 CIN2+ 359 (0.327) HC2 96.3 19.5 37.4
rtHPV 93.3 27.3 38.2
BD HPV 95.0 24.2 37.8
Cobas 95.2 24.0 37.6
AHPV 95.3 28.8 39.3
LBC 88.9 58.1 50.7
CIN3+ 224 (0.204) HC2 98.7 24.0
rtHPV 97.3 24.7
BD HPV 97.8 24.2
Cobas 97.3 23.9
AHPV 97.8 25.1
LBC 92.9 33.1
Mesher et al. [69]
(Predictors 1 +2)
1228 CIN2+ 203 (0.165) HC2 96.0 23.3 20.1
rtHPV 95.0 31.7 22.2
BD HPV 94.0 25.9 21.2
Cobas 94.9 25.0 21.2
AHPV 94.1 34.7 22.3
CIN3+ 97 (0.079) HC2 100 10.1
rtHPV 100 11.2
BD HPV 100 9.4
Cobas 100 9.4
AHPV 99.0 11.2
Dockter et al. [70] Referral 753 Unknown CIN2+ 141 (0.187) HC2 95.0 47.4 97.6 29.4 PreservCyt Yes
AHPV 90.8 56 96 32
CIN3+ 87 (0.115) HC2 98.9 44.4 99.7 18.9
AHPV 97.7 53 99.4 21
Reuschenbach
et al. [71]
Referral 275 28–44 CIN2+ 161 (0.585) HC2 91.5 63.4 83.5 78.5 PreservCyt Yes
AHPV 88.4 71.2 80.6 81.9
CIN3+ 110 (0.4) HC2 96.4 49.1 95.3 55.8
AHPV 95.5 56.4 94.9 59.3
Ratnam et al. [62] Referral 1418 15–80 CIN2+ 401 (0.282) HC2 94.3 38.7 94.5 37.8 PreservCyt Yes
AHPV 96.3 43.2 96.7 40.0
Clad et al. [72] Referral 424 Unknown CIN2+ 252 (0.594) HC2 91.3 61.0 PreservCyt Yes
AHPV 91.7 75.0
LBC 84.9 66.3
CIN3+ 163 (0.384) HC2 95.7 46.0
AHPV 98.2 56.3
LBC 93.9 54.4
Ovestad et al. [48] Referral ASCUS,
LSIL
528 26–69 CIN2+ 47 (0.089) AHPV 98.0 38.0 PreservCyt Yes
Amplicor 100 18.0
Cobas 96.0 26.0
Waldstrom and
Ornskov [73]
Referral LSIL 405 16–65 CIN2+ 67 (0.165) AHPV 92.5 38.2 96.3 22.9 PreservCyt Yes
CIN3+ 31 (0.077) AHPV 93.9 35.5 98.5 11.4
Waldstrom and
Ornskov [55]
Referral ASCUS;
registry f-up on
N=325 for ≥15
months
369 30–69 CIN2+ 48 (0.130) AHPV 87.5 78.0 97.3 40.8 PreservCyt Yes
LAc 93.8 64.3 98.3 31.3
CIN3+ 27 (0.073) AHPV 92.6 73.8 99.1 24.3
LAc 92.6 60.1 98.9 17.4
Waldstrom et al.
[54]
Referral LSIL, 5
year registry f-up
469 16–65 CIN2+ 87 (0.186) AHPV 92.0 36.1 95.2 24.7 PreservCyt Yes
CIN3+ 46 (0.098) AHPV 95.7 33.8 98.6 13.6
Stoler et al. [74]
(CLEAR)
Referral ASCUS 939 ≥21 CIN2+ 91 (0.097) AHPV 86.8 62.9 97.8 20.1 PreservCyt Yes
HC2 88.8 55.8 97.7 18.7
CIN3+ 40 (0.043) AHPV 90.2 60.2 99.3 9.4
HC2 92.3 53.3 99.3 8.5
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Castle et al.
[49,59] (CLEAR)
988 CIN2+ 94 (0.095) AHPV 89.4 63.1 98.3 20.3
Cobas 89.4 59.3 98.1 18.8
CIN3+ 42 (0.043) AHPV 95.2 60.5 99.7 9.7
Cobas 92.9 56.8 99.4 8.7
Rebolj et al. [27]
(Horizon)
≥ASCUS 367 Unknown CIN2+ 119 (0.324) HC2 96 25 SurePath Yes
Cobas 95 31
CLART 94 36
AHPV 89 40
CIN3+ 84 (0.229) HC2 95 22
Cobas 94 27
CLART 93 32
AHPV 87 35
Persson et al. [21] ASCUS/LSIL, 4 years
registry f-up
219 23–60 Triage analysis between LA and AHPV PreservCyt Yes
Binnicker et al.
[50]
≥ASCUS 350 Unknown CIN2+ 81 (0.231) HC2 97.5 27.1 97.3 28.7 PreservCyt Yes
Cobas 91.4 31.2 92.3 28.6
AHPV 91.4 42.0 94.2 32.1
CIN3+ 41 (0.117) HC2 95.1 23.6 97.3 14.2
Cobas 95.1 28.8 97.8 15.1
AHPV 95.1 38.2 98.3 17.0
Cuschieri et al.
[75]
Referral 1336 19–64 CIN2+ 81 (0.061) AHPV 88.9 42.1 PreservCyt Yes
HC2 @ c/o =1 91.4 41.6
HC2 @ c/o =2 91.4 43.9
HC2 @ c/o =10 85.2 51.9
CIN3+ 21 (0.016) AHPV 100 38.5
HC2 @ c/o =1 100 37.6
HC2 @ c/o =2 100 39.6
HC2 @ c/o =10 100 47.7
Moss et al. [25] ASC, LSIL 5455 Unknown Relative performance analysis between HC2, Cervista, rtHPV, COBAS and AHPV PreservCyt Partially
6816 SurePath Partially
Guo et al. [76] Referral ASCUS
LSIL
411 21–69 CIN2+ 72 (0.175) HC2 100 6.2 PreservCyt Yes
AHPV 87.5 32.7
CIN3+ 17 (0.041) HC2 100 5.3
AHPV 94.1 30.2
Johansson et al.
[53]
ASCUS, LSIL,
treated and
untreated; 4.5
years registry
f-up
ASCUS (211) LSIL
(131)
35–87 CIN2+ ASCUS 61 (0.289) AHPV 96.7 12.7 90.5 31.0 SurePath No
CIN2+ LSIL 45 (0.344) 97.8 5.8 83.0 35.2
CIN3+ ASCUS 23 (0.109) 100 12.7 100 14.9
CIN3+ LSIL 20 (0.153) 100 5.8 100 19.8
Test of cure
Persson et al. [56] Test of cure;
average 3.6 years
registry f-up
143 21–56 CIN2/HSIL 5 (0.035) LA 100 80.9 100 21.2 PreservCyt Yes
AHPV 57.1 93.4 97.7 30.8
LBC 85.7 87.5 99.2 26.1
Cubie et al. [57] Test of cure;
National
screening
program; average
13.2 months f-up
1020 Unknown CIN2+ 23 (0.023) HC2 @ c/o =1 100 79.0 100 10.0 Unknown Unknown
HC2 @ c/o =2 96.0 82.0 100 11.0
Cervista 96.0 75.0 100 8.0
AHPV 91.0 84.0 100 12.0
rtHPV 100 78.0 100 9.0
Cobas 100 75.0 100 8.0
Other studies
Heideman et al. [32] 843 <CIN2, 69CIN2+ 912 30–60 CIN2+ 69 (0.076) AHPV 94.2 94.5 PreservCyt Yes
Nolte and Rivbeiro-Nesbitt [77] Samples were selected
by Cervista positivity
(50% positive, 50%
negative) from a
screening population
208 Unknown Agreement analysis between Cervista and AHPV PreservCyt Yes
Nakayama et al.
[78]
Mixed 410 20–76 HSIL 50 (0.121) HC2 98.0 72.4 99.6 33.1 PreservCyt Yes
Amplicor 96.0 71.2 99.2 32.2
AHPV 96.0 76.3 99.3 36.1
Chernesky et al.
[24]
Mixed 580 18–63 CIN2+ 30 (0.052) AHPV 96.6 66.2 99.7 13.3 PreservCyt No
AHPV 93.3 70.9 99.5 14.9 SurePath
CIN: cervical intraepithelial neoplasia, LA: Linear Array HPV Genotyping test (Roche), AHPV: Aptima HPV assay (Hologic), HC2: digene HC2High-Risk HPV DNA Test (Qiagen), rtHPV: RealTime High Risk HPV test (Abbott), LBC: liqid
based cytology, Cobas: cobas HPV test (Roche), CLART: Clinical Array Technology HPV2 assay (Genomica), Amplicor: AMPLICOR® Human Papillomavirus Test (Roche), BD HPV: OnclarityTM HPV Assay (BD), Cervista: Cervista HPV
HR test (Hologic), ASCUS: atypical squamous cells of undetermined signiﬁcance, LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesion, NPV: negative predictive value, PPV: positive
predictive value, f-up: follow-up.
a Included in analysis.
b Veriﬁcation bias adjusted.
c The LA test was considered positive when one or more of the 14 AHPV target HPV types was found.
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Fig. 1. Clinical sensitivities and speciﬁcities for CIN2/3+ detection of the AHPV (orange bars) and HC2 (purple bars) HPV tests from previously published studies on screening
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Notably, the clinical performance of the AHPV test is equiva-
ent to the performance of the cobas HPV test [46–50]—the only
DA-approved HPV test for primary screening to date in the USA.
hus, the AHPV test might be considered suitable for primary cer-
ical cancer screening. Of special interest is the observation by two
ndependentgroups showing thatusageof theAHPVversus theHC2
est in women with abnormal results would lead to a reduced rate
f colposcopy referrals of 21% or 23%, respectively [51,52]. How-
ver, despite fulﬁlling the criteria for HPV DNA test requirements,
PV mRNA based tests are required to undergo further validation
tudies demonstrating a low cumulative CIN3+ incidence rate over
ime following a negative baseline test result [9,42]. So far, ﬁrst
ongitudinal data for the AHPV test are available from studies using
ational registries as follow-up strategy [21,53–57]. These studies
over a range of 6 months to 5 years of passive follow-up periods.
ll but one [56] of these studies found that a positive AHPV result at
aseline is an excellent predictor for future CIN2+ or CIN3+ devel-
pment in referral [21,53–55] or test-of-cure [57] populations. In
rder to ﬁt to current cervical cancer screening intervals based on
he aforementioned randomized controlled trials [35–39], longitu-
inal data are needed from screening settings for a period of at least
hree to ﬁve years [42]. Recently, the ﬁrst longitudinal screening
tudy was published in which AHPV was evaluated as adjunctive
creening test in women 30 years and older. As a result, the CLEAR
rial demonstrated that AHPV testing has a similar sensitivity for
etection of CIN3+ and a signiﬁcantly higher speciﬁcity than the
C2 test. More importantly, the study showed that women with
ILM cytology and with a negative AHPV or HC2 test result at base-
ine have a very similar low risk (<0.3%) of developing CIN3+ after
hree years [58]. These data conﬁrm that the AHPV test is suitable
or primary cervical cancer screening at 3-years intervals.Concerning the AHPV-GT test, only one clinical evaluation study
as been performed to date. The CLEAR trial demonstrated that the
HPV-GT test is both reliable and effective in cervical cancer risk
tratiﬁcation in a referral population [49,59,60].by magenta-colored bars.
7. Conclusions
In summary, this comprehensive review of published litera-
ture on the clinical performance of the Aptima HPV test shows
remarkably similar sensitivity combined with superior speciﬁcity
for CIN2/3+ detection in comparison to the gold-standard HPV
DNA-based test HC2 or GP5+/6+ PCR and throughout very different
study designs.
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